Resolution of Refractory Corneal Neovascularization with Subconjunctival Bevacizumab

Resolution of Refractory Corneal Neovascularization with Subconjunctival Bevacizumab

Blog Article

Corneal neovascularization (CNV) has a variety of causes and threatens corneal clarity, thus optimal visual acuity.Conventional medical management includes topical steroids and matrix metalloproteinase inhibitors like doxycycline.Anti-vascular endothelial growth factor (anti-VEGF) agents have demonstrated promise but remain off-label for this indication.However, these agents hold value in cases refractory to first-line medical management.We report the case of a 90s Low Slung Short 63-year-old woman who presented with ocular rosacea and CNV affecting vision, on a background of acne rosacea.

She was initially treated with fluorometholone and doxycycline, yet continued to deteriorate.Eventually she received two 1.5-mg subconjunctival injections of bevacizumab 2 months apart.CNV completely resolved and results were maintained at 4-year follow-up.This case demonstrates that refractory CNV can be effectively treated with subconjunctival injection of anti-VEGF bevacizumab.

The resolution of CNV was also maintained years after injection with minimal adjunctive therapy during this period, COCONUT REISHI DEODORANT and to our knowledge there are no other studies reporting a follow-up period of 4 years after treatment.This is a pertinent case for other clinicians treating patients in a similar situation.